Markets:

Overview

News

Currencies

International

Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

24.85 +0.78 (+3.24%)

Streaming Delayed Price Updated: 1:48 PM EST, Feb 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

NVIDIA, Tyson Foods, BioNTech And Some Other Big Stocks Moving Lower On Monday ↗

August 08, 2022

AMTD Digital Inc. (NYSE: HKD) dipped 21.8% to $563.71 on possible profit taking after the stock surged over the last few trading days.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022 ↗

August 01, 2022

Upgrades

Via Benzinga

Analyst Ratings for Ultragenyx Pharmaceutical ↗

July 29, 2022

Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings:

Via Benzinga

Ultragenyx Pharma Posts Smaller Than Expected Q2 Loss, Reaffirms Guidance ↗

July 29, 2022

Via Benzinga

Ultragenyx's Neurogenetic Disorder Candidate Shows Favorable Tolerability, Clinical Activity ↗

July 19, 2022

Via Benzinga

Ultragenyx Sells One-Third Of Future North American Crysvita Royalties For $500M ↗

July 14, 2022

Via Benzinga

What 7 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical ↗

July 29, 2022

Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings:

Via Benzinga

Recap: Ultragenyx Pharmaceutical Q2 Earnings ↗

July 28, 2022

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗

July 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Ultragenyx Shares Tumble On Initial Efficacy Missing Expectations, This Analyst Sees 'Viable Path Forward" ↗

July 19, 2022

Via Benzinga

Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher ↗

July 19, 2022

U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite gaining around 3% on Tuesday.

Via Benzinga

Expert Ratings for Ultragenyx Pharmaceutical ↗

May 24, 2022

Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter:

Via Benzinga

Regeneron's Evkeeza Reduces Bad Cholesterol By 48% In Children Aged 5-11 Years ↗

May 23, 2022

Via Benzinga

Earnings Scheduled For July 28, 2022 ↗

July 28, 2022

Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings for its second quarter.

Via Benzinga

July 20, 2022

Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 19, 2022

Via Benzinga

Dow Surges 500 Points; Johnson & Johnson Lowers Guidance ↗

July 19, 2022

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday.

Via Benzinga

This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session ↗

July 19, 2022

Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue...

Via Benzinga

Why U.S. Stocks Are Trading Higher; Housing Starts Drop Further In June ↗

July 19, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 350 points on Tuesday.

Via Benzinga

The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗

July 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap of Monday's Biotech Catalysts - End of the Day Summary ↗

July 18, 2022

Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...

Via Benzinga

What 6 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical ↗

July 01, 2022

Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter:

Via Benzinga

Netflix To $210? Here's The Biggest Price Target Changes For Friday ↗

July 01, 2022

Piper Sandler cut The Goldman Sachs Group, Inc. (NYSE: GS) price target from $430 to $410. Goldman Sachs shares fell 0.1% to $296.79 in pre-market trading.

Via Benzinga

The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate ↗

May 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation ↗

May 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More ↗

May 16, 2022

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from...

Via Benzinga

Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know ↗

May 10, 2022

Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to $146.00. Shares of Ultragenyx Pharmaceutical are trading up 2.9%...

Via Benzinga

What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical ↗

May 06, 2022

Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter:

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Ultragenyx Pharmaceutical's Earnings Outlook ↗

May 04, 2022

Ultragenyx Pharmaceutical (NASDAQ:RARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.